国际标准期刊号: E-2314-7326
P-2314-7334

神经传染病

开放获取

我们集团组织了 3000 多个全球系列会议 每年在美国、欧洲和美国举办的活动亚洲得到 1000 多个科学协会的支持 并出版了 700+ 开放获取期刊包含超过50000名知名人士、知名科学家担任编委会成员。

开放获取期刊获得更多读者和引用
700 种期刊 15,000,000 名读者 每份期刊 获得 25,000 多名读者

索引于
  • 哥白尼索引
  • 谷歌学术
  • 打开 J 门
  • 参考搜索
  • 哈姆达大学
  • 亚利桑那州EBSCO
  • OCLC-世界猫
  • 出租车直达
  • 普布隆斯
  • 日内瓦医学教育与研究基金会
  • ICMJE
分享此页面

抽象的

Preclinical Promise and Translational Challenges of Antioxidants in Central Nervous System Diseases

Ulfuara Shefa

Aerophilic injury is powerfully concerned within the pathologic process of neurodegenerative maladys as well as Alzheimer’s disease, amyotrophic lateral pathology, Huntington’s malady, Parkinson’s malady and stroke (brain ischemia/reperfusion injury). The supply of transgenic and toxin-inducible models of those conditions has expedited the diagnosing analysis of supposed inhibitor agents starting from prototypical natural antioxidants like fat-soluble vitamin (α-tocopherol) to subtle artificial radical traps and chemical action oxidants. Literature review shows that inhibitor therapies have enjoyed general success in diagnosing studies across disparate animal models, however very little profit in human intervention studies or clinical trials. Recent high-profile failures of fat-soluble vitamin trials in Parkinson’s malady, and nitrone therapies in stroke, have diminished enthusiasm to pursue inhibitor neuro protectants within the clinic. The change of location disappointment of antioxidants probably arises from a mix of things as well as failure to grasp the drug candidate’s mechanism of action in relationship to human malady, and failure to conduct diagnosing studies mistreatment concentration and time parameters relevant to the clinical setting. This review discusses the explanation for mistreatment antioxidants within the prevention or mitigation of human neuro diseases, with a vital discussion concerning ways that within which future diagnosing studies could also be adjusted to supply a lot of prophetic worth in choosing agents for translation into human trials.